UBS AM’s CytomX Therapeutics CTMX Stock Holding History

UBS AM’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$824K	Buy	219,779 +30,379	+16%	+$116K	﹤0.01%	2400
2026 Q1	$890K	Buy	+189,400	New	+$961K	﹤0.01%	2380
2021 Q4	–	Sell	-64,369	Closed	-$328K	–	2862
2021 Q3	$328K	Sell	64,369 -480	-0.7%	-$2.57K	﹤0.01%	2604
2021 Q2	$410K	Buy	64,849 +35,254	+119%	+$275K	﹤0.01%	2591
2021 Q1	$229K	Sell	29,595 -19,776	-40%	-$157K	﹤0.01%	2541
2020 Q4	$323K	Hold	49,371	–	–	﹤0.01%	2399
2020 Q3	$328K	Buy	49,371 +18,440	+60%	+$137K	﹤0.01%	2285
2020 Q2	$258K	Buy	30,931 +3,513	+13%	+$32.6K	﹤0.01%	2330
2020 Q1	$210K	Sell	27,418 -7,165	-21%	-$50K	﹤0.01%	2260
2019 Q4	$287K	Sell	34,583 -2,471	-7%	-$16.7K	﹤0.01%	2381
2019 Q3	$273K	Buy	37,054 +8,490	+30%	+$83.8K	﹤0.01%	2485
2019 Q2	$320K	Buy	28,564 +3,974	+16%	+$41.7K	﹤0.01%	2391
2019 Q1	$264K	Buy	24,590 +11,590	+89%	+$171K	﹤0.01%	2363
2018 Q4	$196K	Hold	13,000	–	–	﹤0.01%	2398
2018 Q3	$241K	Buy	13,000 +900	+7%	+$20.5K	﹤0.01%	2360
2018 Q2	$277K	Buy	+12,100	New	+$309K	﹤0.01%	2340

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

UBS AM's CTMX Position: Q2 2026 in Review

UBS AM increased its CytomX Therapeutics (CTMX) stake by 16% in Q2 2026, buying an estimated $116K and bringing the position to 219,779 shares worth $824K. The position accounts for ﹤0.01% of the portfolio, ranked #2400.

UBS AM first reported a position in CTMX in Q2 2018 and has held it in 16 quarters since. The position peaked at $890K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

UBS AM held 219,779 shares of CytomX Therapeutics worth $824K as of Q2 2026.
UBS AM bought 30,379 CytomX Therapeutics shares in Q2 2026, an estimated $116K.
CytomX Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2400 holding.
UBS AM first reported a position in CytomX Therapeutics in Q2 2018 and has held it in 16 quarters since.
UBS AM's CytomX Therapeutics position peaked at $890K in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.